Biovica receives patent approval

2019-04-01 08:00

Uppsala, Sweden, April 1, 2019. Biovica receives an additional patent on the US market for the company PCR-based product.

The patent is a kit-patent that protects against competing companies making copies of Biovicas product. The patent complements previous patent on the US market, which protects the method for the analyzis, making the protection even stronger. The patent is valid until May 2031.

It is important for Biovica to protect our unique technology. Hence, it is very positive that we now strengthen our patent protection on our most important market.”, says Anders Rylander, CEO Biovica.

Some of our Collaborations

>3200

Numbers of patients in studies

24

Publications

10

Pharma Contracts